BridgeBio Oncology Therapeutics (BBOT) Short-term Investments (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Short-term Investments for 3 years, with the latest figure at $199.6 million in Q1 2026.

• Quarterly Short-term Investments changed N/A year-over-year to $199.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $199.6 million (changed N/A YoY) and the FY2025 annual result came in at $51.8 million, down 58.51% from the prior year.
• Short-term Investments advanced to $199.6 million in Q1 2026 per BBOT's latest filing, from $51.8 million in the prior quarter.
• Over five years, Short-term Investments peaked at $199.6 million in Q1 2026 and troughed at $51.8 million in Q4 2025.
• A 3-year average of $108.9 million and a median of $92.2 million in 2024 frame the typical range for Short-term Investments.
• The widest YoY moves for Short-term Investments: up 58.51% in 2025, down 58.51% in 2025.
• Over 3 years, Short-term Investments stood at $124.8 million in 2024, then sank by 58.51% to $51.8 million in 2025, then soared by 285.56% to $199.6 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $199.6 million, $51.8 million, and $59.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.